radiotherapeutics

Oncology

ASCO 2026: Are radiopharmaceuticals being systematically und...

The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.

Oncology

After 'Year of Harvest', Bayer looks to diversify modalities

Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.

R&D

JPM: The calm before the storm for radiotherapeutics

Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.

Oncology

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

Oncology

pharmaphorum podcast Episode 214, Marc Hedrick

On targeted radiotherapeutics, with Marc Hedrick

Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.

Oncology

Health Innovators – Dr Jack Hoppin and Dr John Babich (follo...

The last time we checked in on Ratio Therapeutics co-founders Dr Jack Hoppin and Dr John Babich, they were working out of a WeWork co-working space in downtown Boston, just beginning their

ASCO 2026: Are radiopharmaceuticals being systematically und...

After 'Year of Harvest', Bayer looks to diversify modalities

JPM: The calm before the storm for radiotherapeutics

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

On targeted radiotherapeutics, with Marc Hedrick

Health Innovators – Dr Jack Hoppin and Dr John Babich (follo...

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

radiotherapeutics

Editor's Picks